Bictegravir/emtricitabine/tenofovir-alafenamide/mirtazapineLack of efficacy: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2025年 / 2050卷 / 1期
关键词：
D O I：
10.1007/s40278-025-79085-4
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：115 / 115
相关论文
共 50 条
  • [41] Development of gynecomastia following initiation of bictegravir/emtricitabine/tenofovir alafenamide
    Biagi, M. J.
    Schriever, C. A.
    Chiampas, T. D.
    Michienzi, S. M.
    Patel, M. C.
    Young, J. D.
    Badowski, M. E.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2020, 31 (04) : 380 - 382
  • [42] Real-world experience using bictegravir/emtricitabine/tenofovir-alafenamide (B/F/TAF) in a Scottish HIV cohort
    Proud, E.
    Murphy, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 46 - 47
  • [43] Bictegravir/emtricitabine/tenofovir alafenamideLack of efficacy: 2 case reports
    Reactions Weekly, 2022, 1899 (1) : 98 - 98
  • [44] Cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/doxorubicin-liposomalDrug-induced cardiomyopathy and lack of efficacy
    Reactions Weekly, 2024, 2001 (1) : 103 - 103
  • [45] Network meta-analysis of darunavir/cobicistat/emtricitabine/tenofovir-alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide in treatment-naive patients with HIV-1 infection
    Van Sanden, S.
    Schweikert, B.
    Moecklinghoff, C.
    Tronczynski, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [46] The safety and efficacy of the use of Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) with boosted darunavir in clinical practice
    Tyler, Stephanie
    Collins, Nadine
    Barchi, Will
    Kulasegaram, Ranjababu
    HIV MEDICINE, 2022, 23 : 32 - 32
  • [47] Hepatic safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
    Johnson, M.
    Taylor, S.
    Wei, X.
    Collins, S.
    Martin, H.
    HIV MEDICINE, 2019, 20 : 40 - 40
  • [48] Bictegravir/emtricitabine/tenofovir-alafenamideVirological failure: case report
    Reactions Weekly, 2024, 2023 (1) : 84 - 84
  • [49] Bictegravir/emtricitabine/tenofovir alafenamide after virologic failure to cabotegravir/rilpivirine
    Giguere, Pierre
    Agtarap, Kyla
    McGuinty, Michaeline
    Touchie, Claire
    Kravcik, Steve
    Angel, Jonathan B.
    AIDS, 2025, 39 (06) : 777 - 779
  • [50] Neuropsychiatric, clinical and laboratory changes in patients prospectively switching from elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide to bictegravir/emtricitabine/tenofovir alafenamide
    Tiraboschi, J.
    Prieto, P.
    Saumoy, M.
    Silva, A.
    Imaz, A.
    Scevola, S.
    Fernandez-Olivares, G.
    Navarro-Alcaraz, A.
    Piatti, C.
    Podzamczer, D.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 79 - 80
12345